

Chiara Cremolini

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/2643748/publications.pdf](https://exaly.com/author-pdf/2643748/publications.pdf)

Version: 2025-02-01

250

PR articles

11,407

PR citations

44674

46

PR h-index

32680

99

g-index

277

documents

13470

doc citations

40233

51

h-index

19049

citing authors

#	ARTICLE	IF	CITATIONS
1	Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2025, 22, 28-45.	70.8	19
2	Detecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts' position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2025, 206, 104574.	5.0	5
3	Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2025, 13, e010424.		6
4	Prognostic impact of depth of response and early tumour shrinkage in patients with BRAFV600E-mutated metastatic colorectal cancer treated with targeted therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2025, 17, .	3.6	2
5	A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer. <i>Cancer Cell</i> , 2025, 43, 292-307.e7.	33.0	35
6	Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion. <i>Frontiers in Oncology</i> , 2025, 14, .	2.6	1
7	Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study. <i>ESMO Open</i> , 2025, 10, 104135.	5.3	5
8	Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2025, 13, e010598.		2
9	Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial. <i>ESMO Open</i> , 2025, 10, 104511.	5.3	9
10	EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases. <i>Cancer Treatment Reviews</i> , 2025, 136, 102926.	9.6	9
11	Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2025, , .	1.9	0
12	Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2025, 36, 726-736.	10.0	17
13	Overall Survival Analysis of the Phase III CodeBreakK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. <i>Journal of Clinical Oncology</i> . 2025. 43. 2147-2154.	16.9	16
14	The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2025, 222, 115470.	4.9	3
15	Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2025, 227, 115645.	4.9	0
16	FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials. <i>European Journal of Cancer</i> , 2025, 228, 115713.	4.9	2
17	Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessmentsâ€•analysis of 11 trials by AIO and GONO. <i>Annals of Oncology</i> , 2025, 36, 1307-1318.	10.0	3
18	Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study. <i>Clinical Cancer Research</i> , 2024, 30, 436-443.	6.8	10

#	ARTICLE	IF	CITATIONS
19	Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial. <i>Frontiers in Oncology</i> , 2024, 13, .	2.6	6
20	A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma. <i>Oncologist</i> , 2024, 29, 84-88.	3.4	4
21	Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. <i>European Journal of Cancer</i> , 2024, 199, 113537.	4.9	5
22	Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652â€“3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2024, 30, 2140-2159.	6.8	29
23	Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. <i>British Journal of Cancer</i> , 2024, 130, 1269-1278.	5.5	3
24	Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trials. <i>Cancer Treatment Reviews</i> , 2024, 126, 102735.	9.6	20
25	Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2024, 7, e245635.	6.6	36
26	Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience. <i>ESMO Open</i> , 2024, 9, 102991.	5.3	6
27	Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. <i>Annals of Oncology</i> , 2024, 35, 643-655.	10.0	47
28	Systemic treatment of mismatch repair deficient/microsatellite instability-high metastatic colorectal cancerâ€”single versus double checkpoint inhibition. <i>ESMO Open</i> , 2024, 9, 103483.	5.3	1
29	Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. <i>Journal of Clinical Oncology</i> , 2024, 42, 2637-2644.	16.9	43
30	Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis. <i>European Journal of Cancer</i> , 2024, 207, 114160.	4.9	11
31	Colorectal cancer. <i>Lancet, The</i> , 2024, 404, 294-310.	62.3	258
32	162TiP Phase II study of consolidation treatment with holmium-166 (166Ho) TARE followed by maintenance systemic therapy (MT) in unresectable liver-limited (ULL) colorectal cancer (CRC) patients (pts) after standard first-line induction therapy: The HAITI trial. <i>Annals of Oncology</i> , 2024, 35, S72-S73.	10.0	0
33	108P Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A translational analysis of the TRIPLETE trial. <i>Annals of Oncology</i> , 2024, 35, S50.	10.0	0
34	81P The role of metastasectomy in patients with early onset metastatic colorectal cancer. <i>Annals of Oncology</i> , 2024, 35, S40.	10.0	0
35	Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study. <i>British Journal of Surgery</i> , 2024, 111, .	0.3	4
36	Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study. <i>ESMO Gastrointestinal Oncology</i> , 2024, 5, 100089.	0.6	1

#	ARTICLE	IF	CITATIONS
37	First line therapy in stage IV BRAF mutated colorectal cancer. <i>Heliyon</i> , 2024, 10, e36497.	3.3	4
38	BRAF +ÂEGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2024, 210, 114290.	4.9	8
39	Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial. <i>Annals of Oncology</i> , 2024, 35, 1105-1115.	10.0	16
40	Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden. <i>Therapeutic Advances in Medical Oncology</i> , 2024, 16, .	3.6	3
41	Treatment of Metastatic Colorectal Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2023, 41, 678-700.	16.9	476
42	Demystifying BRAF Mutation Status in Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2023, 278, e540-e548.	4.6	15
43	Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. , 2023, 11, e005493.		22
44	TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients. <i>Tumori</i> , 2023, 109, 481-489.	1.4	1
45	Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials. <i>Cancers</i> , 2023, 15, 2117.	3.8	10
46	An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 2291-2298.	6.8	17
47	Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials. <i>European Journal of Cancer</i> , 2023, 184, 106-116.	4.9	27
48	Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. <i>Frontiers in Oncology</i> , 2023, 12, .	2.6	19
49	Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugsâ€™ development. <i>British Journal of Cancer</i> , 2023, , .	5.5	12
50	Cetuximab as thirdâ€line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wildâ€type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials. <i>Cancer Medicine</i> , 2023, 12, 9392-9400.	2.6	11
51	Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. <i>Annals of Oncology</i> , 2023, 34, 543-552.	10.0	54
52	Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2023, 187, 15-24.	4.9	47
53	Exploring the Outcome of Disappearance or Small Remnants of Colorectal Liver Metastases during First-Line Chemotherapy on Hepatobiliary Contrast-Enhanced and Diffusion-Weighted MR Imaging. <i>Cancers</i> , 2023, 15, 2200.	3.8	3
54	Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study. , 2023, 11, e006633.		31

#	ARTICLE	IF	CITATIONS
55	Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials. <i>European Journal of Cancer</i> , 2023, 189, 112910.	4.9	6
56	Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , 2023, 24, 496-508.	27.4	188
57	Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer: A Multicentre Propensity-Score-Matched Retrospective Analysis. <i>Cancers</i> , 2023, 15, 3064.	3.8	4
58	Trifluridine and Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2023, 388, 1657-1667.	34.6	331
59	Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2023, 29, 3771-3778.	6.8	24
60	Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response. <i>Oncolmmunology</i> , 2023, 12, .	5.4	25
61	Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database. <i>Cancers</i> , 2023, 15, 4117.	3.8	3
62	Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence. <i>Cancers</i> , 2023, 15, 4683.	3.8	0
63	Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV. <i>European Journal of Cancer</i> , 2023, 195, 113396.	4.9	16
64	Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. <i>New England Journal of Medicine</i> , 2023, 389, 2125-2139.	34.6	279
65	Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies. <i>Cancers</i> , 2023, 15, 5451.	3.8	1
66	Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. <i>Nature Medicine</i> , 2023, 30, 271-278.	33.0	101
67	KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2022, 114, 517-527.	4.6	92
68	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 271-279.	4.6	54
69	Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 102, 102301.	9.6	22
70	Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2022, 103, 102326.	9.6	12
71	Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. <i>Clinical Colorectal Cancer</i> , 2022, 21, 141-148.	2.6	22
72	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 161, 90-98.	4.9	18

#	ARTICLE	IF	CITATIONS
73	Upper transversal hepatectomy with double hepatic vein resection and reconstruction to treat colorectal cancer liver metastases at the hepatocaval confluence: a strategy to achieve R0 liver-sparing resection. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1741-1750.	1.5	6
74	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. <i>Oncologist</i> , 2022, 27, e29-e36.	3.4	8
75	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		94
76	Early modulation of Angiotensin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 165, 116-124.	4.9	10
77	The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. <i>Cancer Treatment Reviews</i> , 2022, 106, 102382.	9.6	24
78	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 167, 23-31.	4.9	14
79	Plasma levels of VEGF and VCAM as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4171-4179.	2.6	3
80	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. <i>European Journal of Cancer</i> , 2022, 168, 34-40.	4.9	10
81	Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study. <i>Clinical Cancer Research</i> , 2022, 28, 2818-2829.	6.8	27
82	KDR genetic predictor of toxicities induced by sorafenib and regorafenib. <i>Pharmacogenomics Journal</i> , 2022, 22, 251-257.	2.7	6
83	Fast, Direct Dihydrouracil Quantitation in Human Saliva: Method Development, Validation, and Application. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6033.	2.9	2
84	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 170, 64-72.	4.9	17
85	Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 876-887.	27.4	223
86	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. <i>British Journal of Cancer</i> , 2022, 127, 957-967.	5.5	13
87	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	16.9	65
88	Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2022, 172, 22-30.	4.9	11
89	Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy?. <i>Updates in Surgery</i> , 2022, 74, 1327-1335.	1.7	6
90	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	4.9	25

#	ARTICLE	IF	CITATIONS
91	Impact of baseline gadoteric acid-enhanced liver magnetic resonance and diffusion-weighted imaging in resectable colorectal liver metastases: A prospective, monocentric study. <i>Surgical Oncology</i> , 2022, 44, 101836.	2.1	4
92	RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. <i>Nature Medicine</i> , 2022, 28, 2162-2170.	33.0	95
93	A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). <i>European Journal of Cancer</i> , 2022, 177, 154-163.	4.9	13
94	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECURSE trial. <i>Tumori</i> , 2021, 107, 353-359.	1.4	8
95	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135.	9.6	3
96	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1174-1183.	6.8	53
97	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021, 26, 302-309.	3.4	13
98	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 31-40.	4.9	19
99	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, .	3.6	3
100	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2021, 21, 285-295.	2.7	3
101	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021, 146, 145-154.	4.9	14
102	Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. <i>Nanomaterials</i> , 2021, 11, 661.	4.0	53
103	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1153-1160.	1.9	1
104	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3234-3242.	6.8	34
105	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , 2021, 146, 74-83.	4.9	40
106	EGFR Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1561-1569.	4.6	24
107	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e002501.		27
108	Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study. <i>ESMO Open</i> , 2021, 6, 100073.	5.3	15

#	ARTICLE	IF	CITATIONS
109	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2021, 11, .	3.4	4
110	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 150, 133-142.	4.9	2
111	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2021, 20, 314-317.	2.6	20
112	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , 2021, 125, 839-845.	5.5	17
113	Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study. <i>Clinical Colorectal Cancer</i> , 2021, 20, e253-e262.	2.6	2
114	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1529.	14.4	151
115	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 153, 16-26.	4.9	6
116	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 155, 73-84.	4.9	30
117	Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>ESMO Open</i> , 2021, 6, 100293.	5.3	5
118	Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , 2021, 13, 5715.	3.8	7
119	Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. <i>Cancers</i> , 2020, 12, 2947.	3.8	5
120	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. <i>PLoS ONE</i> , 2020, 15, e0239439.	2.3	10
121	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2020, 139, 81-89.	4.9	20
122	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 138, 1-10.	4.9	40
123	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. <i>ESMO Open</i> , 2020, 5, e001001.	5.3	16
124	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		33
125	Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, .	1.6	12
126	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2146-2154.	1.9	23

#	ARTICLE	IF	CITATIONS
127	Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. <i>Cancers</i> , 2020, 12, 2317.	3.8	48
128	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , 2020, 123, 403-409.	5.5	290
129	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020, 135, 78-88.	4.9	20
130	Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. <i>ESMO Open</i> , 2020, 5, e000698.	5.3	36
131	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. <i>Scientific Reports</i> , 2020, 10, .	3.4	6
132	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. <i>Clinical Colorectal Cancer</i> , 2020, 19, 219-225.	2.6	62
133	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020, 21, 497-507.	27.4	279
134	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 685-698.	2.5	13
135	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. <i>Cancers</i> , 2020, 12, 1742.	3.8	5
136	Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer. <i>International Journal of Cancer</i> , 2020, 146, 2652-2654.	4.3	3
137	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2020, 131, 89-97.	4.9	10
138	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. <i>Cancers</i> , 2020, 12, 1022.	3.8	18
139	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 191-199.e6.	2.6	25
140	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2020, 124, 183-190.	5.5	14
141	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	4.9	68
142	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1268.	14.4	97
143	CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 121, 593-599.	5.5	29
144	Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. <i>Annals of Oncology</i> , 2019, 30, 1969-1977.	10.0	34

#	ARTICLE	IF	CITATIONS
145	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. <i>Pharmacogenomics Journal</i> , 2019, 19, 455-464.	2.7	7
146	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. <i>Pharmacogenomics Journal</i> , 2019, 19, 465-472.	2.7	18
147	Quantitative evidence for early metastatic seeding in colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 1113-1122.	25.2	425
148	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, .	3.4	54
149	The landscape of d16HER2 splice variant expression across HER2-positive cancers. <i>Scientific Reports</i> , 2019, 9, .	3.4	28
150	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019, 18, 116-124.	2.6	9
151	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. <i>European Journal of Cancer</i> , 2019, 111, 138-147.	4.9	7
152	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. <i>International Journal of Cancer</i> , 2019, 145, 2082-2090.	4.3	5
153	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , 2019, 18, e179-e190.	2.6	15
154	Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019, 25, 3954-3961.	6.8	84
155	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019, 4, e000489.	5.3	19
156	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. <i>Biochemical Pharmacology</i> , 2019, 164, 94-105.	5.1	17
157	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 556-563.	2.7	45
158	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182.	4.9	30
159	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. <i>European Journal of Cancer</i> , 2019, 110, 32-41.	4.9	34
160	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. <i>ESMO Open</i> , 2019, 4, e000496.	5.3	5
161	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2019, 18, e8-e19.	2.6	16
162	Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. <i>JAMA Oncology</i> , 2019, 5, 343.	14.4	387

#	ARTICLE	IF	CITATIONS
163	Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 146, 493-501.	2.3	8
164	Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial. <i>Oncotarget</i> , 2019, 10, 2791-2792.	0.3	1
165	Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. <i>Annals of Oncology</i> , 2018, 29, 1528-1534.	10.0	99
166	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e471-e488.	2.6	13
167	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 529.	14.4	105
168	Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. <i>Annals of Oncology</i> , 2018, 29, 924-930.	10.0	122
169	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Handâ€™Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018, 17, e395-e414.	2.6	30
170	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	5.5	20
171	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. <i>Annals of Oncology</i> , 2018, 29, 1394-1401.	10.0	92
172	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	6.8	100
173	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. <i>Clinical Cancer Research</i> , 2018, 24, 784-793.	6.8	24
174	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018, 9, .	13.7	65
175	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018, 23, 1178-1187.	3.4	52
176	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2018, 18, 623-632.	2.7	8
177	A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. <i>Colorectal Cancer</i> , 2018, 7, .	0.0	3
178	The Winding Roadmap of Biomarkers Toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2298.	4.4	4
179	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , 2018, 29, 1800-1806.	10.0	36
180	Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 116, 318-323.	5.5	41

#	ARTICLE	IF	CITATIONS
181	First-line therapy for mCRC – the influence of primary tumour location on the therapeutic algorithm. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 113-113.	70.8	41
182	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. <i>British Journal of Cancer</i> , 2017, 117, 315-321.	5.5	21
183	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	4.6	222
184	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. <i>European Journal of Cancer</i> , 2017, 77, 13-20.	4.9	24
185	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 4312-4322.	6.8	50
186	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2017, 73, 74-84.	4.9	63
187	Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. <i>Annals of Oncology</i> , 2017, 28, 3009-3014.	10.0	110
188	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017, 123, 4506-4514.	4.0	11
189	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017, 2, e000241.	5.3	14
190	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2414-2422.	6.8	170
191	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017, 49, 834-845.	3.3	14
192	How the Lab is Changing Our View of Colorectal Cancer. <i>Tumori</i> , 2016, 102, 541-547.	1.4	15
193	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) Tj ETQq1 1 05784314 rg8T /Ove	7.8	14
194	Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2016, 27, 1810.	10.0	5
195	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 877-885.	2.5	11
196	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994.	3.4	100
197	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. <i>Molecular Cancer Therapeutics</i> . 2016. 15. 1740-1745.	1.9	11
198	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. <i>Annals of Oncology</i> , 2016, 27, 843-849.	10.0	50

#	ARTICLE	IF	CITATIONS
199	What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. PLoS ONE, 2016, 11, e0159146.	2.3	3
200	FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2015, 372, 290-292.	34.6	11
201	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015, 21, 795-801.	33.0	896
202	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2015, 96, 156-166.	5.0	78
203	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, .	4.6	417
204	First-line chemotherapy for mCRC: a review and evidence-based algorithm. Nature Reviews Clinical Oncology, 2015, 12, 607-619.	70.8	157
205	Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysis. European Journal of Cancer, 2015, 51, 800-807.	4.9	53
206	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. British Journal of Cancer, 2015, 112, 1921-1928.	5.5	162
207	Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Annals of Oncology, 2015, 26, 1188-1194.	10.0	177
208	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Molecular Cancer Therapeutics, 2015, 14, 2374-2381.	1.9	4
209	BRAF-mutated metastatic colorectal cancer between past and future. British Journal of Cancer, 2015, 113, 1634-1635.	5.5	11
210	Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. Oncologist, 2015, 20, 1261-1265.	3.4	49
211	TAS-102 for the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2015, 15, 1283-1292.	2.5	14
212	Response. Journal of the National Cancer Institute, 2015, 107, djv205.	4.6	2
213	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncology, The, 2015, 16, 1306-1315.	27.4	987
214	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. Radiotherapy and Oncology, 2015, 117, 315-321.	2.0	34
215	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Annals of Oncology, 2015, 26, 2503.	10.0	23
216	Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. International Journal of Cancer, 2015, 136, 83-90.	4.3	146

#	ARTICLE	IF	CITATIONS
217	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2015, 114, 30-36.	5.5	57
218	KRAS and BRAF genotyping of synchronous colorectal carcinomas. <i>Oncology Letters</i> , 2014, 7, 1532-1536.	1.9	8
219	Biomarkers and Response to Bevacizumab Letter. <i>Clinical Cancer Research</i> , 2014, 20, 1056-1057.	6.8	8
220	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1609-1618.	34.6	973
221	Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. <i>British Journal of Cancer</i> , 2013, 108, 2549-2556.	5.5	54
222	Caveolin-1 is a novel regulator of KRAS-dependent migration in colon carcinogenesis. <i>International Journal of Cancer</i> , 2013, 133, 43-57.	4.3	45
223	Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2013, 2, 411-417.	0.0	1
224	Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. <i>PLoS ONE</i> , 2013, 8, e66774.	2.3	70
225	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2013, 9, 205-214.	3.2	30
226	Prevention and management of adverse events related to regorafenib. <i>Supportive Care in Cancer</i> , 2013, 22, 837-846.	2.2	64
227	Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. <i>Clinical Colorectal Cancer</i> , 2012, 11, 71-76.	2.6	18
228	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. <i>Annals of Oncology</i> , 2012, 23, 1370-1371.	10.0	7
229	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2012, 23, 1207-1213.	10.0	43
230	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 153-160.	0.1	0
231	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer. <i>Cancer</i> , 2012, 118, 1523-1532.	4.0	36
232	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011, 11, .	2.9	72
233	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2011, 104, 1262-1269.	5.5	87
234	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 243-251.	5.0	32

#	ARTICLE	IF	CITATIONS
235	Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis. <i>Journal of the National Cancer Institute</i> , 2011, 103, 21-30.	4.6	177
236	Host Genetic Variants in the IGF Binding Protein-3 Impact on Survival of Patients with Advanced Gastric Cancer Treated with Palliative Chemotherapy. <i>Pharmacogenomics</i> , 2010, 11, 1247-1256.	1.5	6
237	Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting Lost in Translation? <i>Journal of Clinical Oncology</i> , 2010, 28, e173-e174.	16.9	4
238	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. <i>Lancet Oncology</i> , The, 2010, 11, 845-852.	27.4	239
239	Genetic modulation of the Let-7 microRNA binding to KRAS 3' untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab+irinotecan. <i>Pharmacogenomics Journal</i> , 2010, 10, 458-464.	2.7	112
240	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, .	11.3	48
241	Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 167-181.	3.6	7
242	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009, 101, 715-721.	5.5	535
243	First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer. <i>Oncologist</i> , 0, 30, .	3.4	2
244	Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials. <i>British Journal of Cancer</i> , 0, 133, 1297-1306.	5.5	0
245	Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients. <i>ESMO Open</i> , 0, 10, 105756.	5.3	0
246	Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial. <i>Nature Medicine</i> , 0, 31, 3514-3523.	33.0	9
247	Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study. <i>European Journal of Cancer</i> , 0, 230, 116034.	4.9	0
248	Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO. <i>Annals of Oncology</i> , 0, 37, 79-91.	10.0	1
249	Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer patients: demystifying the 100% clinical complete response paradigm. <i>Oncologist</i> , 0, 30, .	3.4	0
250	Switch from cetuximab to panitumumab during encorafenib-based therapy in BRAF V600E mutated metastatic colorectal cancer: An international multicenter analysis from the AGEO group. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 0, 50, 102746.	1.8	0